Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II study of perifosine in combination with bortezomib-with or without
dexamethasone-for patients with relapsed or refractory multiple myeloma previously treated
with bortezomib. The current protocol will enroll patients with relapsed or refractory
multiple myeloma who have been previously treated with bortezomib. The patients will be
treated with perifosine, 50 mg or 100 mg qhs, in combination with bortezomib to determine if
there is any preliminary evidence that the addition of perifosine improves the outcome for
these patients. Previous treatment with perifosine will be allowed in this study. Patients
progressing on treatment with perifosine and bortezomib will receive dexamethasone 20 mg on
days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 of each 21-day cycle in addition to
bortezomib and perifosine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AEterna Zentaris Keryx / AOI Pharmaceuticals, Inc.